NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

flipper44, I actually don't agree with Sluicebox numbers because the 20.2 - 21.2 months that he calculated for the rGBM arm correspond to time from surgery and the 19.3 months for nGBM arm correspond to time from randomization. In order to compare those two numbers, he needs to add 3.1 months (average time between surgery and randomization) to the nGBM arm mOS, So the comparison is 20.2 - 21.2 Vs. 22.4. This means that the patients from the nGBM arm lived longer than the patients from the rGBM arm as would be expected in my opinion.

But I agree with the observation I have seen in some of your posts that DCVax-L might work quite well at crossover because most of them were not on chemo anymore.

And what if those crossover patients are SOC pseudoprogressors initially thought to be SOC progressors. Wouldn't it be even better?

Do you think is possible my theory that part of the 17 difference between the 81 events in the PFS chart (they are not cPFS events, just PFS events) in slide 11 of the trial results presentation and the 64 patients that finally were considered in rGBM arm (81 - 64 =17) correspond to those patients and that is why interim JTM results showed higher mOS than nGBM arm? I would like to know what you and others think about this. I'm not saying I am sure about that. As you said, we will not know for sure until we have more information. Is just that some numbers I calculated support that theory. Not sure if you saw the posts were I shared them.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169301316